A Pathophysiological Role of Plasma Indoxyl Sulfate in Patients with Heart Failure
Background: One of uremic toxins, indoxyl sulfate (IS), is associated with cardiovascular events. This study aimed to measure the plasma IS levels in patients with and without chronic heart failure (CHF). Methods: We measured plasma IS levels in 49 patients with CHF and an estimated glomerular filtr...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taiwan Society of Geriatric Emergency and Critical Medicine (TSGECM)
2017-06-01
|
| Series: | International Journal of Gerontology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S187395981730145X |
| _version_ | 1818559460866523136 |
|---|---|
| author | Miki Imazu Hiroyuki Takahama Kazuhiro Shindo Takuya Hasegawa Hideaki Kanzaki Toshihisa Anzai Hiroshi Asanuma Toshisuke Morita Masanori Asakura Masafumi Kitakaze |
| author_facet | Miki Imazu Hiroyuki Takahama Kazuhiro Shindo Takuya Hasegawa Hideaki Kanzaki Toshihisa Anzai Hiroshi Asanuma Toshisuke Morita Masanori Asakura Masafumi Kitakaze |
| author_sort | Miki Imazu |
| collection | DOAJ |
| description | Background: One of uremic toxins, indoxyl sulfate (IS), is associated with cardiovascular events. This study aimed to measure the plasma IS levels in patients with and without chronic heart failure (CHF).
Methods: We measured plasma IS levels in 49 patients with CHF and an estimated glomerular filtration rate (eGFR) of 40–60 ml/min/1.73 m2 from our institute. These were compared with 31 healthy subjects without CHF (a control), but with comparable eGFR levels, from our resident cohort study. We also test the effect of AST-120 (the oral adsorbent) in 16 CHF patients.
Results: The plasma IS levels in 49 CHF patients increased (1.38 ± 0.84 (SD) vs 0.12 ± 0.07 μg/ml (a control), p < 0.001), and fractional shortening (FS) levels were correlated with the plasma IS levels in these subjects. Second, in our database of the hospitalized CHF patients, we retrospectively reviewed the data for eight CHF patients with stage 3–5 chronic kidney disease (CKD) who received treatment with AST-120, before and one year after treatment, and compared these patients with eight sex-matched CHF patients with stage 3–5 CKD without AST-120. AST-120 decreased plasma IS levels and improved cardiac function.
Conclusions: Plasma IS levels increased in patients with CHF along with cardiac systolic dysfunction compared with those in healthy subjects, and AST-120 improved cardiac dysfunction in patients with CHF. Oral adsorbents may represent a novel treatment for CHF. |
| first_indexed | 2024-12-14T00:25:50Z |
| format | Article |
| id | doaj.art-11fc1453ae514c4e9b1320d33b5ec996 |
| institution | Directory Open Access Journal |
| issn | 1873-9598 |
| language | English |
| last_indexed | 2024-12-14T00:25:50Z |
| publishDate | 2017-06-01 |
| publisher | Taiwan Society of Geriatric Emergency and Critical Medicine (TSGECM) |
| record_format | Article |
| series | International Journal of Gerontology |
| spelling | doaj.art-11fc1453ae514c4e9b1320d33b5ec9962022-12-21T23:25:03ZengTaiwan Society of Geriatric Emergency and Critical Medicine (TSGECM)International Journal of Gerontology1873-95982017-06-01112626610.1016/j.ijge.2016.05.010A Pathophysiological Role of Plasma Indoxyl Sulfate in Patients with Heart FailureMiki Imazu0Hiroyuki Takahama1Kazuhiro Shindo2Takuya Hasegawa3Hideaki Kanzaki4Toshihisa Anzai5Hiroshi Asanuma6Toshisuke Morita7Masanori Asakura8Masafumi Kitakaze9Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, JapanDepartment of Cell Biology, National Cerebral and Cardiovascular Center, Suita, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, JapanDepartment of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Kyoto, JapanDepartment of Laboratory Medicine, Toho University Omori Medical Center, Tokyo, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, JapanBackground: One of uremic toxins, indoxyl sulfate (IS), is associated with cardiovascular events. This study aimed to measure the plasma IS levels in patients with and without chronic heart failure (CHF). Methods: We measured plasma IS levels in 49 patients with CHF and an estimated glomerular filtration rate (eGFR) of 40–60 ml/min/1.73 m2 from our institute. These were compared with 31 healthy subjects without CHF (a control), but with comparable eGFR levels, from our resident cohort study. We also test the effect of AST-120 (the oral adsorbent) in 16 CHF patients. Results: The plasma IS levels in 49 CHF patients increased (1.38 ± 0.84 (SD) vs 0.12 ± 0.07 μg/ml (a control), p < 0.001), and fractional shortening (FS) levels were correlated with the plasma IS levels in these subjects. Second, in our database of the hospitalized CHF patients, we retrospectively reviewed the data for eight CHF patients with stage 3–5 chronic kidney disease (CKD) who received treatment with AST-120, before and one year after treatment, and compared these patients with eight sex-matched CHF patients with stage 3–5 CKD without AST-120. AST-120 decreased plasma IS levels and improved cardiac function. Conclusions: Plasma IS levels increased in patients with CHF along with cardiac systolic dysfunction compared with those in healthy subjects, and AST-120 improved cardiac dysfunction in patients with CHF. Oral adsorbents may represent a novel treatment for CHF.http://www.sciencedirect.com/science/article/pii/S187395981730145XAST-120cardiovascular hemodynamicsheart failureindoxyl sulfate |
| spellingShingle | Miki Imazu Hiroyuki Takahama Kazuhiro Shindo Takuya Hasegawa Hideaki Kanzaki Toshihisa Anzai Hiroshi Asanuma Toshisuke Morita Masanori Asakura Masafumi Kitakaze A Pathophysiological Role of Plasma Indoxyl Sulfate in Patients with Heart Failure International Journal of Gerontology AST-120 cardiovascular hemodynamics heart failure indoxyl sulfate |
| title | A Pathophysiological Role of Plasma Indoxyl Sulfate in Patients with Heart Failure |
| title_full | A Pathophysiological Role of Plasma Indoxyl Sulfate in Patients with Heart Failure |
| title_fullStr | A Pathophysiological Role of Plasma Indoxyl Sulfate in Patients with Heart Failure |
| title_full_unstemmed | A Pathophysiological Role of Plasma Indoxyl Sulfate in Patients with Heart Failure |
| title_short | A Pathophysiological Role of Plasma Indoxyl Sulfate in Patients with Heart Failure |
| title_sort | pathophysiological role of plasma indoxyl sulfate in patients with heart failure |
| topic | AST-120 cardiovascular hemodynamics heart failure indoxyl sulfate |
| url | http://www.sciencedirect.com/science/article/pii/S187395981730145X |
| work_keys_str_mv | AT mikiimazu apathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT hiroyukitakahama apathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT kazuhiroshindo apathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT takuyahasegawa apathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT hideakikanzaki apathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT toshihisaanzai apathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT hiroshiasanuma apathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT toshisukemorita apathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT masanoriasakura apathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT masafumikitakaze apathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT mikiimazu pathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT hiroyukitakahama pathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT kazuhiroshindo pathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT takuyahasegawa pathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT hideakikanzaki pathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT toshihisaanzai pathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT hiroshiasanuma pathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT toshisukemorita pathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT masanoriasakura pathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure AT masafumikitakaze pathophysiologicalroleofplasmaindoxylsulfateinpatientswithheartfailure |